Alnylam Adds on Sales, Looks to Pipeline for Further Growth

Alnylam Pharmaceuticals (NASDAQ: ALNY) continued its launch of Onpattro for transthyretin-mediated amyloidosis with solid quarter-over-quarter growth as the biotech looks to its pipeline to further boost its revenue.Alnylam Pharmaceuticals results: The raw numbers Metric Q2 2019 Q2 2018 Change Revenue $44.7 million $29.9 million 49% Income from operations ($236 million) ($192 million) N/A Earnings per…

How Do Analysts See Sartorius Stedim Biotech S.A. (EPA:DIM) Performing In The Next 12 Months?

After Sartorius Stedim Biotech S.A.’s (EPA:DIM) earnings announcement in June 2019, analysts seem cautiously bearish, with earnings expected to grow by 12% in the upcoming year relative to the higher past 5-year average growth rate of 22%. Presently, with latest-twelve-month earnings at €208m, we should see this growing to €233m by 2020. Below is a…

Is Sarepta Therapeutics a Bad News Buy?

Over the past couple of weeks, the market has shaved a few billion dollars from Sarepta Therapeutics’ (NASDAQ: SRPT) market value, thanks to a pair of upsetting developments. Has this former top-performing biotech stock been beaten down too far, or should investors remain braced for more losses ahead? Here’s what you need to know.View photosGuy with a magnifying…

Why Zogenix Stock Sank Today

What happenedShares of Zogenix (NASDAQ: ZGNX) closed Monday about 8.5% lower, a decline precipitated by the biotech’s announcement that it plans to acquire privately held Modis Therapeutics for $250 million. So whatInvesting in biotech stocks, especially clinical-stage biotechs, is fraught with risk for a number of reasons. Zogenix’s drop on Monday highlights the downsides of such…

3 Embarrassingly Cheap Dividend Stocks

High yields. Low valuations. But with a couple of downsides to be aware of. What’s better than a stock that pays you to own it? How about a stock that pays you to own it and is also really cheap? Many investors, especially retirees, love dividend stocks because they pay out dividends on a regular…

3 Top Small-Cap Stocks to Buy in August

These small-cap stocks hold the potential to deliver big-time returns. Keith Speights, Keith Noonan, and Reuben Gregg Brewer Want to hear a secret to success in investing that not everyone knows? Buy small-cap stocks. Between 1926 and 2006, small-cap stocks delivered a compound annual growth rate (CAGR) of 12.7% while the S&P 500 index generated…